Medical Watch Disease & Treatment News

• CRISPR and newer editors are being tested in blood disorders, liver diseases, high cholesterol, and hereditary angioedema
• Direct gene-editing...

• Patient impact: Eligible adults with untreated dMMR/MSI-H stage II/III rectal cancer can now receive dostarlimab alone, potentially skipping...

Beam Therapeutics will share initial Phase I/II results for BEAM-301, an LNP base-editing therapy targeting the R83C mutation in GSDIa, at ESGCT.

-...

World AMR Awareness Week 2026 pairs its "One Health, one action" theme with a clear look at how misuse drives resistance.

• Misuse fuels resistance:...

• $8 million CIRM award supports the ongoing open-label Phase 1/2 trial of EPI-321.
• The one-time epigenetic therapy targets DUX4 expression without...

• Survival gains: Immune checkpoint inhibitor-based downstaging linked to longer median overall survival (4.6 vs 2.5 years) and recurrence-free...

Alzheimer’s Research UK is advocating for a new Dementia Drugs Fund to give patients access to treatments like lecanemab and donanemab while the NHS...

Biomarker testing unlocks targeted oncology drugs but often stalls at tissue collection, test ordering, and result interpretation.

• Practical fixes:...

• In-vivo editing delivers CRISPR instructions inside the body, usually to the liver via one infusion.
• This approach remains investigational and...

Earlier CAR T adoption in multiple myeloma hinges on coordinated care and toxicity vigilance, not just trial data or guideline shifts.

• Guideline...

Patient-derived organoids can predict responses to conventional chemotherapy and validate targeted therapy vulnerabilities, including drug...

Does the new OncoPrism-NSCLC validation truly justify changing how doctors pick immunotherapy?

• Core claims: High scorers showed significantly...

Mayo Clinic's 2006 report detailed four CLL patients achieving partial responses after taking green tea extract, following lab evidence that EGCG...

Consolidation chemotherapy plus PD-1 inhibitor after definitive chemoradiotherapy extended survival in locally advanced ESCC.

• Survival gains:...

AbbVie is showcasing its widest ESMO program yet, spanning seven assets across lung, colorectal, ovarian, prostate and gastric cancers using ADCs,...

HER2 (ERBB2) overexpression or amplification drives aggressive tumor behavior and poor outcomes, especially in breast and gastric cancers.

• Lacking...

• REMS elimination recognized as safe, enabling more centers to offer CAR T.
• Caregiver needs dropped to 2 weeks and driving restrictions eased,...

Cancer genomics and precision oncology can improve patient outcomes and strengthen health systems, but only when scaled equitably, sustainably, and according to evidence.

Head-to-head testing in 327 human blood samples reveals clear differences in how quickly mRNA and lipid components decline across Moderna, Pfizer, and...

• Tedopi combos hit 46-47% 1-year OS in phase 2 metastatic NSCLC versus 29% with docetaxel alone, a topline signal to be presented October 25.
  -...